TY - JOUR
T1 - Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea
AU - Camilleri, Michael
AU - Carlson, Paula
AU - Bousaba, Joelle
AU - McKinzie, Sanna
AU - Vijayvargiya, Priya
AU - Magnus, Yorick
AU - Sannaa, Wassel
AU - Wang, Xiao Jing
AU - Chedid, Victor
AU - Zheng, Ting
AU - Maselli, Daniel
AU - Atieh, Jessica
AU - Taylor, Ann
AU - Nair, Asha A.
AU - Kengunte Nagaraj, Nagaswaroop
AU - Johnson, Stephen
AU - Chen, Jun
AU - Burton, Duane
AU - Busciglio, Irene
N1 - Funding Information:
Funding MC is supported from National Institutes of Health (NIH) (grant number: R01-DK115950). The study was facilitated by the CCaTS Clinical Research Trials Unit at Mayo Clinic (grant number: UL1-TR002377) from NIH.
Publisher Copyright:
©
PY - 2023/1
Y1 - 2023/1
N2 - Objective There are altered mucosal functions in irritable bowel syndrome with diarrhoea (IBS-D); ∼30% of patients with IBS-D have abnormal bile acid (BA) metabolism (ABAM) and diarrhoea (summarised as BAD). Aim To compare biochemical parameters, gastrointestinal and colonic transit, rectal sensation and pathobiological mechanisms in IBS-D without ABAM and in BAD (serum 7C4>52 ng/mL). Design In patients with Rome III criteria of IBS-D, we compared biochemical features, colonic transit, rectal sensation, deep genotype of five BA-related genes, ileal and colonic mucosal mRNA (differential expression (DE) analysis) and stool dysbiosis (including functional analysis of microbiome). Results in BAD were compared with IBS-D without ABAM. Results Compared with 161 patients with IBS-D without ABAM, 44 patients with BAD had significantly faster colonic transit, lower microbial alpha diversity, different compositional profile (beta diversity) and higher Firmicutes to Bacteroidetes ratio with evidence of decreased expression of bile acid thiol ligase (involved in transformation of primary to secondary BAs) and decreased sulfatases. In BAD (compared with IBS-D without ABAM), terminal ileal biopsies showed downregulation of SLC44A5 (a BA transporter), and ascending colon biopsies showed upregulation in barrier-weakening genes (CLDN2), serine protease inhibitors, immune activation, cellular differentiation and a cellular transporter (FABP6; BA binding). No DE of genes was documented in descending colon biopsies. The two groups had similar rectal sensation. Conclusion Though sharing clinical symptoms with IBS-D, BAD is associated with biological differences and mechanisms that have potential to enhance diagnosis and treatment targeting barrier dysfunction, inflammatory and microbial changes.
AB - Objective There are altered mucosal functions in irritable bowel syndrome with diarrhoea (IBS-D); ∼30% of patients with IBS-D have abnormal bile acid (BA) metabolism (ABAM) and diarrhoea (summarised as BAD). Aim To compare biochemical parameters, gastrointestinal and colonic transit, rectal sensation and pathobiological mechanisms in IBS-D without ABAM and in BAD (serum 7C4>52 ng/mL). Design In patients with Rome III criteria of IBS-D, we compared biochemical features, colonic transit, rectal sensation, deep genotype of five BA-related genes, ileal and colonic mucosal mRNA (differential expression (DE) analysis) and stool dysbiosis (including functional analysis of microbiome). Results in BAD were compared with IBS-D without ABAM. Results Compared with 161 patients with IBS-D without ABAM, 44 patients with BAD had significantly faster colonic transit, lower microbial alpha diversity, different compositional profile (beta diversity) and higher Firmicutes to Bacteroidetes ratio with evidence of decreased expression of bile acid thiol ligase (involved in transformation of primary to secondary BAs) and decreased sulfatases. In BAD (compared with IBS-D without ABAM), terminal ileal biopsies showed downregulation of SLC44A5 (a BA transporter), and ascending colon biopsies showed upregulation in barrier-weakening genes (CLDN2), serine protease inhibitors, immune activation, cellular differentiation and a cellular transporter (FABP6; BA binding). No DE of genes was documented in descending colon biopsies. The two groups had similar rectal sensation. Conclusion Though sharing clinical symptoms with IBS-D, BAD is associated with biological differences and mechanisms that have potential to enhance diagnosis and treatment targeting barrier dysfunction, inflammatory and microbial changes.
KW - BARRIER FUNCTION
KW - BILE ACID
KW - BILE ACID METABOLISM
KW - DIARRHOEA
KW - INFLAMMATION
UR - http://www.scopus.com/inward/record.url?scp=85130860129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130860129&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2022-327471
DO - 10.1136/gutjnl-2022-327471
M3 - Article
C2 - 35580964
AN - SCOPUS:85130860129
SN - 0017-5749
VL - 72
SP - 54
EP - 65
JO - Gut
JF - Gut
IS - 1
ER -